Comparative Pharmacology
Head-to-head clinical analysis: ESTRADIOL CYPIONATE versus OGEN 625.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ESTRADIOL CYPIONATE versus OGEN 625.
ESTRADIOL CYPIONATE vs OGEN .625
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Estradiol cypionate is a synthetic ester of estradiol, a form of estrogen. It binds to estrogen receptors (ERα and ERβ) in target tissues, modulating gene expression and leading to effects such as development of female secondary sexual characteristics, regulation of menstrual cycle, and maintenance of reproductive tissues. It also has effects on bone density, lipid metabolism, and coagulation factors.
Estrogen replacement therapy; estrogen binds to estrogen receptors, which then translocate to the nucleus and modulate gene transcription, leading to effects such as proliferation of the endometrium and regulation of gonadotropin secretion.
1-5 mg intramuscularly every 3-4 weeks.
0.625 mg orally once daily
None Documented
None Documented
Terminal elimination half-life is approximately 7–9 days following intramuscular injection, reflecting prolonged absorption from the oil depot.
Estrone: 10-24 hours; equilin: 12-18 hours; terminal half-life supports once-daily dosing.
Primarily renal (approximately 90% as glucuronide and sulfate conjugates; less than 5% as unchanged drug). Biliary/fecal elimination accounts for about 10%.
Renal (primarily as glucuronide and sulfate conjugates, ~50-80% of a dose), fecal (~10-20%), with enterohepatic recirculation.
Category D/X
Category C
Estrogen
Estrogen